Here’s thing
Analysts are calling $187 per Sarepta share
That’s almost a MC of 18 billion $$
At the moment Sarepta have a MC of $16 billion
earnings are $353 million but they are yet to make a profit..
Some say Sarepta could earn $1 billion next year ?
Now
All the drugs have not shown efficacy or produced the end points in their trails
The FDA has definitely set a PRECEDENT
ok
So one can ask?
What’s it got to do with PER ?
In my opinion as long as the Tox study is a given
I firmly believe Atl1102 will be a winner
In DMD and LGMD
Do the sums .. a MC of $5 billion is reachable $$
https://www.bloomberg.com/news/newsl
https://www.bloomberg.com/news/newsl
FDA approves Sareptas Srp901 for the whole population, page-40
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $90.15M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 10.0¢ | $47.27K | 463.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 319942 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 86442 | 3 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| PER (ASX) Chart |